Published in J Virol on June 01, 1989
Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci U S A (1990) 1.54
The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. J Virol (1992) 1.41
Monocyte maturation controls expression of equine infectious anemia virus. J Virol (1994) 1.29
Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J Virol (1998) 1.22
Characterization of variable regions in the envelope and S3 open reading frame of equine infectious anemia virus. J Virol (1991) 1.21
Biological characterization of Rev variation in equine infectious anemia virus. J Virol (1998) 1.14
Equine infectious anemia virus derived from a molecular clone persistently infects horses. J Virol (1990) 1.13
Identification of a hypervariable region in the long terminal repeat of equine infectious anemia virus. J Virol (1991) 1.13
Characterization of early pathogenic effects after experimental infection of calves with bovine immunodeficiency-like virus. J Virol (1992) 1.11
Endocytosis and a low-pH step are required for productive entry of equine infectious anemia virus. J Virol (2005) 1.01
Isolation and characterization of new wild-type isolates of bovine lentivirus. J Virol (1993) 0.97
Equine infectious anemia virus entry occurs through clathrin-mediated endocytosis. J Virol (2007) 0.92
Characterization of a cytolytic strain of equine infectious anemia virus. J Virol (2003) 0.90
Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype. J Virol (2003) 0.89
Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain. J Virol (2006) 0.88
Identification of transactivation-response sequences in the long terminal repeat of bovine immunodeficiency-like virus. J Virol (1993) 0.86
In vivo replicative status and envelope heterogeneity of equine infectious anemia virus in an inapparent carrier. J Virol (1994) 0.85
Equine endothelial cells support productive infection of equine infectious anemia virus. J Virol (1998) 0.85
Localized sequence heterogeneity in the long terminal repeats of in vivo isolates of equine infectious anemia virus. J Virol (1997) 0.85
Inhibition of lentivirus replication by aqueous extracts of Prunella vulgaris. Virol J (2009) 0.83
An equine infectious anemia virus variant superinfects cells through novel receptor interactions. J Virol (2008) 0.82
Disease induction by virus derived from molecular clones of equine infectious anemia virus. J Virol (1998) 0.82
Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism. J Virol (2005) 0.77
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol (1981) 13.11
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science (1988) 11.05
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Equine infectious anemia virus gag and pol genes: relatedness to visna and AIDS virus. Science (1986) 4.09
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Immunodiffusion reaction in equine infectious anemia. Cornell Vet (1970) 3.51
Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus. Virology (1986) 3.24
Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature (1985) 3.13
Chemical and immunological characterizations of equine infectious anemia virus gag-encoded proteins. J Virol (1987) 3.02
Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J Biol Chem (1984) 3.02
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages. Infect Immun (1983) 2.52
Production of equine infectious anemia antigen in a persistently infected cell line. Arch Gesamte Virusforsch (1973) 2.19
Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. Virology (1987) 2.19
Immunofluorescent localization of equine infectious anemia virus in tissue. Am J Pathol (1971) 1.80
Human T-cell lymphotropic virus type III shares sequence homology with a family of pathogenic lentiviruses. Proc Natl Acad Sci U S A (1986) 1.80
Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. J Virol (1982) 1.64
Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56
Virulence and in vitro growth of a cell-adapted strain of equine infectious anemia virus after serial passage in ponies. Am J Vet Res (1982) 1.45
Equine infectious anemia virus: evidence favoring classification as a retravirus. J Virol (1976) 1.42
Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses. Virology (1980) 1.36
Propagation and titration of equine infectious anemia virus in horse leukocyte culture. Natl Inst Anim Health Q (Tokyo) (1967) 1.27
Pseudotyping of dual-tropic recombinant viruses generated by infection of mice with different ecotropic murine leukemia viruses. Virology (1985) 1.25
Leukemia induction by a new strain of Friend mink cell focus-inducing virus: synergistic effect of Friend ecotropic murine leukemia virus. J Virol (1984) 1.19
Some observations on carriers of equine infectious anemia. J Am Vet Med Assoc (1955) 1.15
Characterization of the serological cross-reactivity between glycoproteins of the human immunodeficiency virus and equine infectious anaemia virus. J Gen Virol (1988) 0.98
Molecular cloning and physical characterization of integrated equine infectious anemia virus: molecular and immunologic evidence of its close relationship to ovine and caprine lentiviruses. Virology (1986) 0.98
In vitro host range of equine infectious anemia virus. Intervirology (1981) 0.97
Detection of equine infectious anemia virus in horse leukocyte cultures derived from horses in various stages of equine infectious anemia viral infection. Am J Vet Res (1984) 0.93
Attempts to cultivate the equine infectious anemia virus in various types of cells. Natl Inst Anim Health Q (Tokyo) (1968) 0.92
Responses in horses infected with equine infectious anemia virus adapted to tissue culture. Am J Vet Res (1979) 0.88
Changes in pathogenicity of equine infectious anemia virus during passages in horse leukocyte cultures. Natl Inst Anim Health Q (Tokyo) (1970) 0.81
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol (1978) 1.66
The ultrastructure of normal and pathological IgM immunoglobulins. J Exp Med (1968) 1.64
Effect of murine host genotype on MCF virus expression, latency, and leukemia cell type of leukemias induced by Friend murine leukemia helper virus. Virology (1983) 1.62
Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res (1991) 1.61
Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
Purification and ultrastructure of Aleutian disease virus of mink. Nature (1975) 1.47
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol (1976) 1.41
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol (1989) 1.38
Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad Sci U S A (1979) 1.38
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36
Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem (1998) 1.35
Sequences in the U5-gag-pol region influence early and late pathogenic effects of Friend and Moloney murine leukemia viruses. J Virol (1990) 1.34
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines. J Gen Virol (1988) 1.28
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Pseudotyping of dual-tropic recombinant viruses generated by infection of mice with different ecotropic murine leukemia viruses. Virology (1985) 1.25
Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells. J Virol (1990) 1.24
Leukemia induction by a new strain of Friend mink cell focus-inducing virus: synergistic effect of Friend ecotropic murine leukemia virus. J Virol (1984) 1.19
Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol (1995) 1.18
Monoclonal antibodies against Aleutian disease virus distinguish virus strains and differentiate sites of virus replication from sites of viral antigen sequestration. J Virol (1986) 1.18
Characterization of a neurologic disease induced by a polytropic murine retrovirus: evidence for differential targeting of ecotropic and polytropic viruses in the brain. J Virol (1995) 1.18
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
Murine leukemia virus infectious centers are dependent on the rate of virus production by infected cells. Virology (1978) 1.16
A 60-kDa prion protein (PrP) with properties of both the normal and scrapie-associated forms of PrP. J Biol Chem (1995) 1.15
Influence of the murine MHC (H-2) on Friend leukemia virus-induced immunosuppression. J Exp Med (1986) 1.15
The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes. J Virol (1998) 1.15
Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology (1998) 1.14
Identification of a hypervariable region in the long terminal repeat of equine infectious anemia virus. J Virol (1991) 1.13
Persistence of infectious Friend virus in spleens of mice after spontaneous recovery from virus-induced erythroleukemia. J Virol (1979) 1.13
Cloning of a gene whose expression is increased in scrapie and in senile plaques in human brain. Science (1985) 1.13
N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro. J Biol Chem (2001) 1.12
Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med (1988) 1.11
Transmissible spongiform encephalopathies and prion protein interconversions. Adv Virus Res (2001) 1.11
Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update. Mol Biotechnol (1999) 1.10
Fine mapping of the friend retrovirus resistance gene, Rfv3, on mouse chromosome 15. J Virol (1999) 1.10
Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J Neurochem (1998) 1.09
Host genes conferring resistance to a central nervous system disease induced by a polytropic recombinant Friend murine retrovirus. J Virol (1990) 1.07
Neurologic disease induced by polytropic murine retroviruses: neurovirulence determined by efficiency of spread to microglial cells. J Virol (1997) 1.06
Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents. Biotechniques (1991) 1.05
Ultrastructure of gamma-M immunoglobulin and alpha macroglobulin: electron-microscopic study. Science (1967) 1.05
Ultrastructural studies of human and rabbit alpha-M-globulins. J Exp Med (1968) 1.05
In vitro expression in eukaryotic cells of a prion protein gene cloned from scrapie-infected mouse brain. Proc Natl Acad Sci U S A (1988) 1.04
Precipitation of human serum proteins by polyethyleneglycol. Clin Chim Acta (1968) 1.04
MCF-specific murine monoclonal antibodies made against AKR-247 MCF virus recognize a unique determinant associated with the gp70-p-15(E) complex. J Virol (1982) 1.03
Analysis of linkage between scrapie incubation period and the prion protein gene in mice. J Gen Virol (1990) 1.02
Differing T-cell requirements for recombinant retrovirus vaccines. J Virol (1996) 1.02
Cytotoxic T lymphocyte recognition of gp70 on Friend virus-induced erythroleukemia cell clones. J Immunol (1980) 1.02
Influence of MHC genes on spontaneous recovery from Friend retrovirus-induced leukemia. J Immunol (1992) 1.01
Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein. J Immunol (1991) 1.01
Protease sensitivity and nuclease resistance of the scrapie agent propagated in vitro in neuroblastoma cells. J Virol (1991) 1.00
Differences in cytokine and chemokine responses during neurological disease induced by polytropic murine retroviruses Map to separate regions of the viral envelope gene. J Virol (2001) 1.00